Pelthos Therapeutics Inc.

Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026 11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the second quarter of 2026, representing a 48% quarter-over-quarter increase in units dispensed More than 25,000 patients have now been prescribed Zelsuvmi since it was commercially launched in July 2025 Management will host a conference call today, August 13, 2026, at 8:30 a.m. ET DURHAM, N.C., Aug. 13, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos,” “we” or the “Company”), today announced its financial results for the second quarter ended June 30, 2026, which can be found in the Financial Results section of the Company’s website at https://ir.pelthos.com/financial-info/financial-results. Second Quarter and Recent Highlights Zelsuvmi, the first at-home FDA-approved treatment (ages 1 and above) for molluscum contagiosum, a highly contagious viral skin infection that largely afflicts children, was launched in July 2025 and has generated $42.3 million in net sales in the first four quarters of commercial operations. As of June 30, 2026, 29,126 units of Zelsuvmi have been dispensed and […] The post Pelthos Therapeutics Announces Second Quarter 2026 Financial Results appeared first on Pelthos Therapeutics.

Company to hold a conference call at 8:30 a.m. ET DURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026. The company will hold a conference call followed by a question-and-answer period at 8:30 a.m. Eastern Time. Details for the conference call can be found below: Date: Thursday, August 13, 2026 Time: 8:30 a.m. Eastern Time Toll Free: 1-877-451-6152 International: 1-201-389-0879 Conf.ID: 13761132 Call.Me: Participants can use the dial-in numbers above or click the CallMe link for instant telephone access to the event. The CallMe link will be activated 15 minutes prior to the scheduled call start time. Webcast: Participants can also join via the web at https://viavid.webcasts.com/starthere.jsp?ei=1767131&tp_key=12eae87cb3 About Pelthos TherapeuticsPelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI® (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s […] The post Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026 appeared first on Pelthos Therapeutics.

DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of the close of business on August 4, 2026 are entitled to notice of and to vote at the 2026 Annual Meeting. The Company anticipates filing the Notice of Annual Meeting and proxy statement in early August 2026. The date of the 2026 Annual Meeting represents a change of more than 30 days from the anniversary of the Company’s 2025 Annual Meeting. Given the adjustment, stockholder proposals pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended, must be received in writing by the Company before the close of business on August 3, 2026 to be considered for inclusion in the Company’s proxy materials for the 2026 Annual Meeting. About Pelthos TherapeuticsPelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI® (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy […] The post Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders appeared first on Pelthos Therapeutics.

DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that the company was added as a member of the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap® Growth Benchmark Indexes effective when the US market opened on June 29 as part of the 2026 Russell indexes reconstitution. The June Russell US Indexes reconstitution captures up to the 4,000 largest US stocks as of Thursday, April 30th, ranking them by total market capitalization. Beginning in 2026, the Russell US Indexes are reconstituted on a semi-annual basis (in June and December), and membership in the Russell Microcap® Index remains in place until the next scheduled reconstitution. Membership in the Russell Microcap® Index also means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. “We are pleased to be included in these Russell indexes, which reflect the significant progress Pelthos has made since becoming a public company. Over the past year, we have executed on our strategy, expanding our product portfolio and strengthening our […] The post Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes appeared first on Pelthos Therapeutics.

DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that CEO Scott Plesha will present at 11:05 am ET and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. Investors interested in arranging one-on-one meetings should contact their Jefferies representative. About Pelthos Therapeutics Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI® (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s portfolio of assets includes XEPI® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and XEGLYZE® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X. Contacts Investors: LifeSci Advisors, LLC Mike Moyer, Managing Director mmoyer@lifesciadvisors.com Media: KWM Communications Kellie Walsh pelthos@kwmcommunications.com (914) 315-6072 The post Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference appeared first on Pelthos Therapeutics.